Targeting MAGL in brain support cells to help people with Alzheimer’s
Official title: Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease
Funded at University of Texas Hlth Science Center · NIH-11457057 · Data updated 2026-11-12
This project aims to lower MAGL activity in brain support cells (astrocytes) to reduce inflammation and protect memory in people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $771,678 |
| NIH project number | 4R01AG081362-02 |
| Project ID | NIH-11457057 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with Alzheimer’s disease—particularly those in earlier stages when inflammation-driven damage may be modifiable—would be the eventual candidates for this approach.
✕Less likely to help
Patients with non-Alzheimer’s dementias or very advanced neurodegeneration may not benefit from this specific MAGL-targeting approach.
What this research studies
From a patient's perspective, researchers are using a virus-based gene tool to turn off the MAGL enzyme specifically in astrocytes, the brain's support cells, in laboratory models of Alzheimer's. They will look at whether this astrocyte-specific approach reduces brain inflammation, lessens buildup of Alzheimer’s-related proteins, and preserves memory-related function in those models. The team will compare targeted astrocyte silencing to broader MAGL suppression because past studies showed global inhibition can cause side effects. If the targeted approach works in the lab, it could form the basis for developing safer treatments for people with Alzheimer’s.
Why it matters
Potential benefit: If successful, this approach could reduce neuroinflammation and protect neurons, potentially slowing cognitive decline in Alzheimer's disease.
How similar studies have gone: Preclinical animal studies have shown that blocking MAGL can reduce Alzheimer's pathology, but global MAGL suppression caused adverse effects, so astrocyte-specific targeting is a newer strategy.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Chen, Chu — University of Texas Hlth Science Center
- Study coordinator: Chen, Chu
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.